Juvenal Tobin W sold $50K of CSTL
Juvenal Tobin W (Chief Commercial Officer) sold 1,301 shares of CASTLE BIOSCIENCES INC (CSTL) at $38.39 on 2025-11-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CCO’s open-market sale of 1,301 shares at $38.3900, totaling about $49,945, with holdings after the sale of 77,694 shares, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note insider selling, but the 10b5-1 structure and modest size relative to company fundamentals make this unlikely to drive a durable repricing.
What to watch
The sale date (Nov 24, 2025) predates the filing by months, and the transaction is explicitly pre-arranged, which weakens any inference about current outlook.
Background
The article is a SEC Form 4 insider transaction disclosure for Castle Biosciences (CSTL).
Ticker impact
Castle Biosciences disclosed an insider open-market sale by its Chief Commercial Officer under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely sentiment-only and should fade unless accompanied by other news.
The filing is a disclosed sale of 1,301 shares at $38.39 under a 10b5-1 plan, which typically reduces signaling value versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so traders may briefly price in a sentiment overhang.
Key entities
- issuerCASTLE BIOSCIENCES INC
Company whose insider transaction was disclosed on Form 4.
- insiderJuvenal Tobin W
Chief Commercial Officer who sold shares under a 10b5-1 plan.
